Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry

Martine Ploeg, Katja K. Aben, Christina A. Hulsbergen-van de Kaa, Mark P. Schoenberg, Johannes A. Witjes, Lambertus A. Kiemeney

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: Nonurothelial malignancies represent a small fraction of bladder malignancies and are less extensively studied, resulting in sparse empirical data on these tumors. We sought insight into tumor characteristics and survival. Materials and Methods: Data were obtained from the nationwide Netherlands Cancer Registry on patient and tumor characteristics, and followup in all patients with primary invasive (T1 or greater) bladder tumors in The Netherlands between 1995 and 2006. Data were analyzed using frequency tables. Relative survival analysis was done. Results: We identified 28,807 patients with invasive bladder cancer, of whom 7.7% presented with nonurothelial carcinoma. Mean patient age range at diagnosis of adenocarcinoma and soft tissue tumors was 66.4 years, and 78.3 years at diagnosis of nonspecified tumors. Most histological subtypes were more common in males except squamous cell carcinoma and lymphoma. Muscle invasion was seen in 52.2% of urothelial carcinoma cases vs 87.5%, 71.9% and 89.0% of squamous cell carcinoma, adenocarcinoma and neuroendocrine tumor cases, respectively. For urothelial carcinoma, squamous cell carcinoma and adenocarcinoma women presented at more advanced stage. In the neuroendocrine group this stage difference was the opposite. Survival analysis showed a 5-year relative survival rate of 32.2%, 22.9%, 31.8% and 21.1% for T2 or greater urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors, respectively. Conclusions: Patients with nonurothelial carcinoma present at more advanced stage and overall have worse survival. Relative survival of muscle invasive adenocarcinoma equals survival of muscle invasive urothelial carcinoma. For stage II and III disease these cases do even better. Muscle invasive squamous cell carcinoma and neuroendocrine tumors show worse survival regardless of stage.

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalJournal of Urology
Volume183
Issue number3
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Netherlands
Registries
Epidemiology
Squamous Cell Carcinoma
Adenocarcinoma
Carcinoma
Neuroendocrine Tumors
Neoplasms
Muscles
Survival Analysis
Survival
Lymphoma
Urinary Bladder
Survival Rate

Keywords

  • morbidity
  • Netherlands
  • urinary bladder
  • urinary bladder neoplasms
  • urothelium

ASJC Scopus subject areas

  • Urology

Cite this

Clinical Epidemiology of Nonurothelial Bladder Cancer : Analysis of The Netherlands Cancer Registry. / Ploeg, Martine; Aben, Katja K.; Hulsbergen-van de Kaa, Christina A.; Schoenberg, Mark P.; Witjes, Johannes A.; Kiemeney, Lambertus A.

In: Journal of Urology, Vol. 183, No. 3, 03.2010, p. 915-920.

Research output: Contribution to journalArticle

Ploeg, Martine ; Aben, Katja K. ; Hulsbergen-van de Kaa, Christina A. ; Schoenberg, Mark P. ; Witjes, Johannes A. ; Kiemeney, Lambertus A. / Clinical Epidemiology of Nonurothelial Bladder Cancer : Analysis of The Netherlands Cancer Registry. In: Journal of Urology. 2010 ; Vol. 183, No. 3. pp. 915-920.
@article{650dc24190a04c05ab6ec53c3e10451c,
title = "Clinical Epidemiology of Nonurothelial Bladder Cancer: Analysis of The Netherlands Cancer Registry",
abstract = "Purpose: Nonurothelial malignancies represent a small fraction of bladder malignancies and are less extensively studied, resulting in sparse empirical data on these tumors. We sought insight into tumor characteristics and survival. Materials and Methods: Data were obtained from the nationwide Netherlands Cancer Registry on patient and tumor characteristics, and followup in all patients with primary invasive (T1 or greater) bladder tumors in The Netherlands between 1995 and 2006. Data were analyzed using frequency tables. Relative survival analysis was done. Results: We identified 28,807 patients with invasive bladder cancer, of whom 7.7{\%} presented with nonurothelial carcinoma. Mean patient age range at diagnosis of adenocarcinoma and soft tissue tumors was 66.4 years, and 78.3 years at diagnosis of nonspecified tumors. Most histological subtypes were more common in males except squamous cell carcinoma and lymphoma. Muscle invasion was seen in 52.2{\%} of urothelial carcinoma cases vs 87.5{\%}, 71.9{\%} and 89.0{\%} of squamous cell carcinoma, adenocarcinoma and neuroendocrine tumor cases, respectively. For urothelial carcinoma, squamous cell carcinoma and adenocarcinoma women presented at more advanced stage. In the neuroendocrine group this stage difference was the opposite. Survival analysis showed a 5-year relative survival rate of 32.2{\%}, 22.9{\%}, 31.8{\%} and 21.1{\%} for T2 or greater urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors, respectively. Conclusions: Patients with nonurothelial carcinoma present at more advanced stage and overall have worse survival. Relative survival of muscle invasive adenocarcinoma equals survival of muscle invasive urothelial carcinoma. For stage II and III disease these cases do even better. Muscle invasive squamous cell carcinoma and neuroendocrine tumors show worse survival regardless of stage.",
keywords = "morbidity, Netherlands, urinary bladder, urinary bladder neoplasms, urothelium",
author = "Martine Ploeg and Aben, {Katja K.} and {Hulsbergen-van de Kaa}, {Christina A.} and Schoenberg, {Mark P.} and Witjes, {Johannes A.} and Kiemeney, {Lambertus A.}",
year = "2010",
month = "3",
doi = "10.1016/j.juro.2009.11.018",
language = "English (US)",
volume = "183",
pages = "915--920",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical Epidemiology of Nonurothelial Bladder Cancer

T2 - Analysis of The Netherlands Cancer Registry

AU - Ploeg, Martine

AU - Aben, Katja K.

AU - Hulsbergen-van de Kaa, Christina A.

AU - Schoenberg, Mark P.

AU - Witjes, Johannes A.

AU - Kiemeney, Lambertus A.

PY - 2010/3

Y1 - 2010/3

N2 - Purpose: Nonurothelial malignancies represent a small fraction of bladder malignancies and are less extensively studied, resulting in sparse empirical data on these tumors. We sought insight into tumor characteristics and survival. Materials and Methods: Data were obtained from the nationwide Netherlands Cancer Registry on patient and tumor characteristics, and followup in all patients with primary invasive (T1 or greater) bladder tumors in The Netherlands between 1995 and 2006. Data were analyzed using frequency tables. Relative survival analysis was done. Results: We identified 28,807 patients with invasive bladder cancer, of whom 7.7% presented with nonurothelial carcinoma. Mean patient age range at diagnosis of adenocarcinoma and soft tissue tumors was 66.4 years, and 78.3 years at diagnosis of nonspecified tumors. Most histological subtypes were more common in males except squamous cell carcinoma and lymphoma. Muscle invasion was seen in 52.2% of urothelial carcinoma cases vs 87.5%, 71.9% and 89.0% of squamous cell carcinoma, adenocarcinoma and neuroendocrine tumor cases, respectively. For urothelial carcinoma, squamous cell carcinoma and adenocarcinoma women presented at more advanced stage. In the neuroendocrine group this stage difference was the opposite. Survival analysis showed a 5-year relative survival rate of 32.2%, 22.9%, 31.8% and 21.1% for T2 or greater urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors, respectively. Conclusions: Patients with nonurothelial carcinoma present at more advanced stage and overall have worse survival. Relative survival of muscle invasive adenocarcinoma equals survival of muscle invasive urothelial carcinoma. For stage II and III disease these cases do even better. Muscle invasive squamous cell carcinoma and neuroendocrine tumors show worse survival regardless of stage.

AB - Purpose: Nonurothelial malignancies represent a small fraction of bladder malignancies and are less extensively studied, resulting in sparse empirical data on these tumors. We sought insight into tumor characteristics and survival. Materials and Methods: Data were obtained from the nationwide Netherlands Cancer Registry on patient and tumor characteristics, and followup in all patients with primary invasive (T1 or greater) bladder tumors in The Netherlands between 1995 and 2006. Data were analyzed using frequency tables. Relative survival analysis was done. Results: We identified 28,807 patients with invasive bladder cancer, of whom 7.7% presented with nonurothelial carcinoma. Mean patient age range at diagnosis of adenocarcinoma and soft tissue tumors was 66.4 years, and 78.3 years at diagnosis of nonspecified tumors. Most histological subtypes were more common in males except squamous cell carcinoma and lymphoma. Muscle invasion was seen in 52.2% of urothelial carcinoma cases vs 87.5%, 71.9% and 89.0% of squamous cell carcinoma, adenocarcinoma and neuroendocrine tumor cases, respectively. For urothelial carcinoma, squamous cell carcinoma and adenocarcinoma women presented at more advanced stage. In the neuroendocrine group this stage difference was the opposite. Survival analysis showed a 5-year relative survival rate of 32.2%, 22.9%, 31.8% and 21.1% for T2 or greater urothelial carcinoma, squamous cell carcinoma, adenocarcinoma and neuroendocrine tumors, respectively. Conclusions: Patients with nonurothelial carcinoma present at more advanced stage and overall have worse survival. Relative survival of muscle invasive adenocarcinoma equals survival of muscle invasive urothelial carcinoma. For stage II and III disease these cases do even better. Muscle invasive squamous cell carcinoma and neuroendocrine tumors show worse survival regardless of stage.

KW - morbidity

KW - Netherlands

KW - urinary bladder

KW - urinary bladder neoplasms

KW - urothelium

UR - http://www.scopus.com/inward/record.url?scp=75849129336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75849129336&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.11.018

DO - 10.1016/j.juro.2009.11.018

M3 - Article

C2 - 20083267

AN - SCOPUS:75849129336

VL - 183

SP - 915

EP - 920

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -